PDB35 Estimating the Real Life Daily Usage and Daily Cost of GLP-1 Receptor Agonists in the UK Setting

Value in Health - United Kingdom
doi 10.1016/j.jval.2011.08.1338
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

The Cardiovascular Effects of GLP-1 Receptor Agonists

Cardiovascular Therapeutics
MedicineCardiovascular MedicinePharmacologyCardiology
2010English

Primary-Care Observational Database Study of the Efficacy of GLP-1 Receptor Agonists and Insulin in the UK

Diabetic Medicine
Internal MedicineEndocrinologyMetabolismDiabetes
2013English

Role and Development of GLP-1 Receptor Agonists in the Management of Diabetes

Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
Internal MedicinePharmacology
2009English

The Time When the Daily Life Intersects the Non-Daily Life

Contemporary Sociological Studies
1991English

Cardiovascular Effects of Glucagon-Like Peptide 1 (GLP-1) Receptor Agonists

Cardiovascular Diabetology
Internal MedicineCardiologyEndocrinologyCardiovascular MedicineMetabolismDiabetes
2014English

Β-Arrestin-Biased Agonists of the GLP-1 Receptor From Β-Amino Acid Residue Incorporation Into GLP-1 Analogues

Journal of the American Chemical Society
BiochemistryColloidCatalysisChemistrySurface Chemistry
2016English

Evaluating Preferences for Profiles of GLP-1 Receptor Agonists Among Injection-Naïve Type 2 Diabetes Patients in the UK

Patient Preference and Adherence
PharmacologyHealth PolicyMedicineToxicologySocial SciencesPharmaceutics
2015English

Pdb68 - Cost-Effectiveness Analysis of Exenatide Versus GLP-1 Receptor Agonists in Patients With Type 2 Diabetes Mellitus

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Overactivity in Daily Life

Pain
NeurologyAnesthesiologyPain MedicinePharmacology
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy